A little more than a year past disappointing Phase III results from a cannabinoid receptor-targeted drug for cancer pain, GW Pharmaceuticals PLC is basking in investor enthusiasm for positive Phase III results with a different candidate in the class being tested in the orphan disease Dravet syndrome.
The London-headquartered biotech announced March 14 that Epidiolex (cannabidiol) produced a statistically significant reduction in convulsive seizures suffered by patients with Dravet, a pediatric-onset form of epilepsy
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?